Nuvation Bio Inc. Convertible Debt
Nuvation Bio Inc. (NUVB) had Convertible Debt of $242.62 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:ConvertibleDebt · last filed 2026-08-06
- 2026-06-30: Convertible Debt $242.62M.
- 2025-12-31: Convertible Debt $0.00.
| Period end | Convertible Debt |
|---|---|
| 2026-06-30 | $242.62M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |